Ongoing and future research efforts have focused on investigating novel immune checkpoints, such as TIGIT, LAG-3, and TIM-3, as well as newer therapies such as CAR-T targeting GPC-3, AFP, and other proteins expressed on HCC tumors, potentially providing greater advances and the expansion of the therapeutic armamentarium in HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.